Regeneron Pharmaceuticals

New York
Pharmaceuticals Biotechnology and Life Sciences

Corporate Bias Rating

Expand Summary

Risk Level:

Rating - Danger
High Risk


Regeneron Pharmaceuticals scored an 85 on the 2023 Corporate Equality Index (CEI) from the Human Rights Campaign (HRC), a political stakeholder group. By complying with Human Rights Campaign’s controversial demands, Regeneron increases the risk of dividing employees, alienating customers and harming shareholders. The company covers transgender-related medical costs for its employees and their children. It also uses sex and gender ideology criteria in employee recruitment, vendor selection, marketing, and philanthropic support. Regeneron uses its reputation, corporate funds, and political influence to support controversial sex and gender ideologies, organizations, and legislation. It also has pledged to work with the Human Rights Campaign (HRC) to create a more "diverse" brand. Regeneron does not provide viewpoint protections for its employees. However, Regeneron has not publicly terminated business relationships due to religious beliefs or political views. For these reasons, Regeneron receives a High Risk rating.

Shareholder Proposals

Expand Summary

ESG Category
Summary of ResolutionMgmt RecTotal Vote % in Favor
6/9/23SocialBoston Common Asset ManagementReport on a process by which access to medicine is considered in matters related to protecting intellectual propertyAgainst9.38%
Generate Reports